Next Article in Journal
Sex Differences in Lipid Profile across the Life Span in Patients with Type 2 Diabetes: A Primary Care-Based Study
Next Article in Special Issue
Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
Previous Article in Journal
Can Deep Learning Using Weight Bearing Knee Anterio-Posterior Radiograph Alone Replace a Whole-Leg Radiograph in the Interpretation of Weight Bearing Line Ratio?
Article

Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients

1
Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
2
Department of Hematology, The 901st Hospital of the Joint Logistics Support Force of PLA, Hefei 230032, China
*
Author to whom correspondence should be addressed.
Academic Editors: Tadeusz Robak and Helen A. Papadaki
J. Clin. Med. 2021, 10(8), 1768; https://doi.org/10.3390/jcm10081768
Received: 8 February 2021 / Revised: 28 March 2021 / Accepted: 9 April 2021 / Published: 19 April 2021
(This article belongs to the Special Issue Myeloid-Derived Suppressor Cells (MDSCs) in Haematology)
Myeloid-derived suppressor cells (MDSCs) are defined as negative regulators that suppress the immune response through a variety of mechanisms, which usually cluster in cancer, inflammation, and autoimmune diseases. This study aims to investigate the correlation between M-MDSCs and the clinical features of diffuse large B-cell lymphoma (DLBCL) patients, as well as the possible accumulation mechanism of M-MDSCs. The level of M-MDSCs is significantly increased in newly diagnosed and relapsed DLBCL patients. Regarding newly diagnosed DLBCL patients, the frequency of M-MDSCs is positively correlated with tumor progression and negatively correlated with overall survival (OS). More importantly, the level of M-MDSCs can be defined as a biomarker for a poor prognosis in DLBCL patients. Additionally, interleukin-35 (IL-35) mediates the accumulation of M-MDSCs in DLBCL patients. Anti-IL-35 treatment significantly reduces levels of M-MDSCs in Ly8 tumor-bearing mice. Thus, M-MDSCs are involved in the pathological process of DLBCL. Targeting M-MDSCs may be a promising therapeutic strategy for the treatment of DLBCL patients. View Full-Text
Keywords: myeloid-derived suppressor cells; diffuse large B-cell lymphoma; interleukin-35; tumor progression; prognosis; immunosuppression myeloid-derived suppressor cells; diffuse large B-cell lymphoma; interleukin-35; tumor progression; prognosis; immunosuppression
Show Figures

Figure 1

MDPI and ACS Style

Wang, Z.; Jiang, R.; Li, Q.; Wang, H.; Tao, Q.; Zhai, Z. Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients. J. Clin. Med. 2021, 10, 1768. https://doi.org/10.3390/jcm10081768

AMA Style

Wang Z, Jiang R, Li Q, Wang H, Tao Q, Zhai Z. Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients. Journal of Clinical Medicine. 2021; 10(8):1768. https://doi.org/10.3390/jcm10081768

Chicago/Turabian Style

Wang, Zhitao, Rui Jiang, Qian Li, Huiping Wang, Qianshan Tao, and Zhimin Zhai. 2021. "Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients" Journal of Clinical Medicine 10, no. 8: 1768. https://doi.org/10.3390/jcm10081768

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop